Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain.
The bovine papillomavirus E5 transforming protein appears to activate both the epidermal growth factor receptor (EGF-R) and the platelet-derived growth factor receptor (PDGF-R) by a ligand-independent mechanism. To further investigate the ability of E5 to activate receptors of different classes and to determine whether this stimulation occurs through the extracellular domain required for ligand activation, we constructed chimeric genes encoding PDGF-R and EGF-R by interchanging the extracellular, membrane, and cytoplasmic coding domains. Chimeras were transfected into NIH 3T3 and CHO(LR73) cells. All chimeras expressed stable protein which, upon addition of the appropriate ligand, could be activated as assayed by tyrosine autophosphorylation and biological transformation. Cotransfection of E5 with the wild-type and chimeric receptors resulted in the ligand-independent activation of receptors, provided that a receptor contained either the transmembrane domain of the PDGF-R or the cytoplasmic domain of the EGF-R. Chimeric receptors that contained both of these domains exhibited the highest level of E5-induced biochemical and biological stimulation. These results imply that E5 activates the PDGF-R and EGR-R by two distinct mechanisms, neither of which specifically involves the extracellular domain of the receptor. Consistent with the biochemical and biological activation data, coimmunoprecipitation studies demonstrated that E5 formed a complex with any chimera that contained a PDGF-R transmembrane domain or an EGF-R cytoplasmic domain, with those chimeras containing both domains demonstrating the greatest efficiency of complex formation. These results suggest that although different domains of the PDGF-R and EGF-R are required for E5 activation, both receptors are activated directly by formation of an E5-containing complex.
Cohen
B D
BD
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892.
Goldstein
D J
DJ
Rutledge
L
L
Vass
W C
WC
Lowy
D R
DR
Schlegel
R
R
Schiller
J T
JT
D016475:3T3 Cells; D000818:Animals; D052688:Bovine papillomavirus 1 / Q000235:genetics* / Q000378:metabolism; D016466:CHO Cells; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002471:Cell Transformation, Neoplastic; D002772:Cholera Toxin / Q000494:pharmacology; D003001:Cloning, Molecular; D006224:Cricetinae; D066246:ErbB Receptors / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism*; D006801:Humans; D046911:Macromolecular Substances; D051379:Mice; D008961:Models, Structural; D009856:Oncogene Proteins, Viral / Q000302:isolation & purification / Q000378:metabolism*; D011485:Protein Binding; D017479:Receptors, Platelet-Derived Growth Factor / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000302:isolation & purification / Q000378:metabolism; D014162:Transfection
D046911:Macromolecular Substances; D009856:Oncogene Proteins, Viral; D011993:Recombinant Fusion Proteins; C054304:oncogene protein E5, Bovine papillomavirus type 1; D002772:Cholera Toxin; D066246:ErbB Receptors; D017479:Receptors, Platelet-Derived Growth Factor